Vor Bio's gene editing stem cell therapy makes significant progress, with the stock price surging over 70% in after-hours trading

According to the latest information from the Wise Finance APP, Vor Bio (VOR.US), whose stock price has been falling since its listing, seems to have ushered in a "super reversal". The company's stock price surged by more than 70% in after-hours trading on Thursday in the U.S. stock market, following the positive data reported by the company on its gene-editing stem cell therapy trem-cel for the treatment of acute myeloid leukemia (AML). The phase 1/2 trial data of the gene-editing stem cell therapy trem-cel in combination with Mylotarg for the treatment of AML showed positive results, demonstrating the potential synergistic effect and drug safety. It is understood that Vor Bio's phase 1/2 study, named VBP101, is intensively evaluating the efficacy of trem-cel in combination with Mylotarg from the U.S. pharmaceutical giant Pfizer (PFE.US) for relapsed/refractory AML patients. In a statement, Vor (VOR) stated that the research data "demonstrated reliable engraftment, shielded Mylotarg's targeted toxicity, significantly expanded the therapeutic window of Mylotarg, and provided early evidence of broad patient benefit". The company also added that it plans to engage with the U.S. Food and Drug Administration (FDA) by the end of the year to discuss the core pivotal trial design of the trem-cel plus Mylotarg treatment combination. Core pivotal trials are generally the final stage for approving new drugs, which means that if these trials are successful, trem-cel is expected to enter the market rapidly. Vor also announced that the company is conducting a study that will enable another candidate therapy (an antibody-drug conjugate called VADC45) to enter phase 1 testing. This diversified product pipeline progress demonstrates the company's research and development strength and long-term potential in the field of cancer treatment. The latest positive trial results of Vor Bio's joint drug trial with Pfizer indicate that trem-cel may have significant potential in future AML treatment, enhancing investors' confidence in the company's prospects. Gene editing therapy is considered one of the breakthrough therapies in the future of cancer treatment. As a research-stage company focused on developing innovative gene-editing stem cell therapies, any subtle signs of clinical success by Vor Bio will quickly attract the attention of investors and some retail speculative forces. Based on this, some investors have begun to have high expectations for the positive outlook of the trem-cel and Mylotarg combination, which is also one of the reasons driving the sudden surge in Vor Bio's stock price after hours